

RANITIN INJECTION 2ml

For the use of a Registered Medical Practitioner or Hospital or a Laboratory only.
Abbreviated Prescribing information for RANITIN INJ 2ml (Ranitidine Hydrochloride Injection I.P.)

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

Mechanism of action: Pharmacotherapeutic group: H₂-receptor antagonists

ATC code: A02BA02

Ranitidine is a specific, rapidly acting histamine H₂-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion.

DOSAGE AND ADMINISTRATION: As directed by physician.

CONTRAINDICATION:

Ranitidine is contraindicated in patients with a known hypersensitivity to ranitidine or any of the excipients.

WARNINGS & PRECAUTIONS: Malignancy, renal disease, bradycardia, acute porphyric attacks, in elderly patients, persons with chronic lung disease, diabetes or the immunocompromised increased risk of developing community acquired pneumonia. Post-marketing data indicate reversible mental confusion, depression, and hallucinations, reported most frequently in severely ill and elderly patients.

DRUG INTERACTION: 1) Inhibition of cytochrome P450-linked mixed function oxygenase system: does not potentiate the actions of drugs, which are inactivated by this enzyme system such as diazepam, lidocaine, phenytoin, propranolol and theophylline. Also, altered prothrombin time with coumarin anticoagulants (e.g. warfarin). 2) Competition for renal tubular secretion: may reduce the excretion of procainamide and N-acetylprocainamide. 3) Alteration of gastric pH: increase in absorption (e.g. triazolam, midazolam, glipizide) or a decrease in absorption (e.g. ketoconazole, atazanavir, delaviridine, gefitinib, also decreases erlotinib exposure).

ADVERSE REACTIONS: Leucopenia, thrombocytopenia, agranulocytosis or pancytopenia, with marrow hypoplasia or marrow aplasia, Hypersensitivity reactions (urticaria, angioneurotic oedema, fever, bronchospasm, hypotension and chest pain), Anaphylactic shock, Dyspnoea, Reversible mental confusion, depression and hallucinations, Headache (sometimes severe), dizziness and reversible involuntary movement disorder, blurred vision, bradycardia, A-V block, asystole, cardiac arrest and tachycardia, Vasculitis, abdominal pain, constipation, nausea, acute pancreatitis, diarrhoea, Hepatitis, Skin Rash, Erythema multiforme, alopecia, arthralgia and myalgia, Acute interstitial nephritis, impotence, breast symptoms and breast conditions (such as gynaecomastia and galactorrhoea).

Marketed BY:

Torrent Pharmaceuticals Ltd.

Indrad-382 721, Dist. Mehsana, India.

At: Plot No. J-174, J-168, J-168/1,

MIDC, Tarapur, District: Thane- 401 506.

IN/RANITIN INJ 25 mg/FEB-2022/03/ABPI

(Additional information is available on request)